Advanced Diffusion Imaging in Renal Cancer Patients

Launched by NYU LANGONE HEALTH · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial, called "Advanced Diffusion Imaging in Renal Cancer Patients," is looking at a special type of imaging to help better understand kidney tumors. The study aims to determine if the tumors are cancerous and what type of cancer they are, as well as to predict whether a person's kidney function will stay stable or decline after surgery to remove part of the kidney.

To take part in this trial, participants need to be adults aged between 21 and 85 who have been scheduled for a specific type of kidney surgery called laparoscopic partial nephrectomy. They should also have a certain level of kidney function, measured by a test called eGFR, which must be above 30. Participants will need to feel comfortable with the imaging process and will not be eligible if they have certain metal implants, are pregnant, or experience severe anxiety in small spaces. If eligible, participants can expect to undergo advanced imaging tests before and after their surgery to help gather important information that could improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Renal mass patients scheduled for laparoscopic partial nephrectomy.
• • eGFR above 30 ml/min/m2.
• • Ages 21 to 85
• • Must be willing and able to provide consent.
• Exclusion Criteria:
• • All metal implants and dental implants that have ferromagnetic properties and are unsafe at 3.0 T.
• • Pregnant women are not eligible for participating in this study.
• • Acute claustrophobia